<DOC>
	<DOCNO>NCT02308644</DOCNO>
	<brief_summary>To evaluate effect contrast sensitivity ( CS ) measurement intravitreal bevacizumab injection associate standard metabolic control eye diabetic macular edema ( DME ) associate standard metabolic control .</brief_summary>
	<brief_title>Intravitreous Bevacizumab Standard Metabolic Control Diabetic Macular Edema - A Contrast Sensitivity Study</brief_title>
	<detailed_description>Prospective , randomize , mask interventional study . Patients diabetes mellitus ( DM ) 2 , glycated hemoglobin ( HbA1c ) less 11 % previously treat macular edema three month randomize two group . The baseline examination consist visual acuity ( VA ) , CS use Pelli-Robson Charts , optical coherence tomography ( OCT ) Fluorescein Angiography eye . The test repeat , group , , week 2,6 12 , data collect analysis end close phase . On day start open phase , apply intravitreal injection bevacizumab group test close phase hold week 14,18 24 study complete [ Table 1 ] . Patients monitor control clinically include blood pressure measurement , laboratory blood test blood glucose , glycated hemoglobin , urea , creatinine , total cholesterol fraction .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age least 18 year old , gender ; Patients diabetes mellitus type I type II ; Macular edema presence clinically significant diabetic mixed diffuse ; Visual acuity worse 20/40 correct ( &lt; 68 letter ETDRS ) Glycated hemoglobin â‰¤ 11 % ; Systolic diastolic blood pressure &lt; 170 &lt; 100 mmHg , respectively ; Women pregnant ; Free inform consent term sign screen visit ; Ability adhere visit . Failure comply inclusion criterion ; Treatment DME within prior 3 month ; Vitreoretinal traction within 1 disc diameter ( DD ) fovea , clinically confirm OCT ; Atrophy fibrosis surround fovea ; Any level cataract ; Vitreous hemorrhage opacity mean ; Eye disease relate diabetic retinopathy derail central vision ( eg Age Macula Degeneration , chorioretinitis scar , ... ) Bestcorrected visual acuity 20/40 ( &gt; 68 letter ETDRS ) Inability understand treatment term consent ; Debilitating systemic disorder preclude patient 's admission study , accord clinical judgment investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>intravitreal bevacizumab</keyword>
	<keyword>Contrast Sensitivity</keyword>
</DOC>